Overview

Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation

Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The prevention of graft rejection after liver transplantation benefits nowadays from a variety of newly developed immunosuppressive agents. This allows more flexible and individualized immunoprophylaxis and gives an opportunity to reduce the long-term side effects (hypertension, renal failure, diabetes, etc.) of immunosuppression. The purpose of this study is to evaluate, in liver transplanted patients, if low doses of tacrolimus, given in combination with mycophenolate mofetil, can result in a lower rate of long-term side effects without increasing the rate of graft rejection.
Phase:
Phase 3
Details
Lead Sponsor:
Rennes University Hospital
Collaborator:
Ministry of Health, France
Treatments:
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus